Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Separately, Zacks Investment Research upgraded Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Wednesday, July 26th.

Shares of Ekso Bionics Holdings (NASDAQ:EKSO) traded up $0.48 on Friday, reaching $2.39. The company had a trading volume of 9,378,693 shares, compared to its average volume of 674,949. Ekso Bionics Holdings has a 12 month low of $0.99 and a 12 month high of $4.90. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18.

Ekso Bionics Holdings (NASDAQ:EKSO) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. sell-side analysts anticipate that Ekso Bionics Holdings will post -0.81 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ekso Bionics Holdings, Inc. (EKSO) Stock Rating Upgraded by ValuEngine” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/11/18/ekso-bionics-holdings-inc-ekso-stock-rating-upgraded-by-valuengine.html.

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after purchasing an additional 176,197 shares during the last quarter. National Planning Corp lifted its position in shares of Ekso Bionics Holdings by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after purchasing an additional 286,492 shares during the last quarter. Carl Domino Inc lifted its position in shares of Ekso Bionics Holdings by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after purchasing an additional 102,734 shares during the last quarter. Finally, Intellectus Partners LLC lifted its position in shares of Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after purchasing an additional 5,294 shares during the last quarter. Institutional investors and hedge funds own 2.85% of the company’s stock.

Ekso Bionics Holdings Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.